Incyte Settles with DOJ Over Alleged Kickbacks
The U.S. Department of Justice (DOJ) has cracked down on yet another drugmaker accused of paying kickbacks, reaching a settlement with Incyte and adding to the numerous agreements it’s reached in recent years with high-profile pharma companies over alleged kickbacks.
Incyte, a Delaware-based biopharma company best known for its myelofibrosis drug Jakafi (ruxolotinib), agreed to fork over $12.6 million to settle allegations that it used an independent foundation as a funnel for paying federal beneficiary copays for patients from November 2011 through December 2014.
The DOJ claimed that the company was the only donor to a fund that was established for paying the copays of certain federal beneficiaries taking Jakafi. But the patients did not have myelofibrosis and thus were ineligible for the fund, the department said.
Incyte denied any wrongdoing and stressed that its settlement with the government is not an admission of liability.